Rgenta Therapeutics Inc.

Rgenta Therapeutics Inc. company information, Employees & Contact Information

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.

Company Details

Employees
30
Founded
-
Address
300 Tradecenter, Suite 6600,united States
Email
in****@****atx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Woburn, Massachusetts
Looking for a particular Rgenta Therapeutics Inc. employee's phone or email?

Rgenta Therapeutics Inc. Questions

News

Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators - Yahoo Finance

Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators Yahoo Finance

Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC) - Yahoo Finance

Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC) Yahoo Finance

Rgenta Therapeutics Announces Formation of Repeat Expansion Diseases Focused Scientific Advisory Board - PR Newswire

Rgenta Therapeutics Announces Formation of Repeat Expansion Diseases Focused Scientific Advisory Board PR Newswire

Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML) - The Manila Times

Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML) The Manila Times

Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financing - PR Newswire

Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financing PR Newswire

Rgenta Therapeutics Raises $52M in Series A Financing - PR Newswire

Rgenta Therapeutics Raises $52M in Series A Financing PR Newswire

Rgenta Therapeutics Enters into a Collaboration with Lundbeck - PR Newswire

Rgenta Therapeutics Enters into a Collaboration with Lundbeck PR Newswire

Rgenta Therapeutics Launches with $20 Million Seed Investment - PR Newswire

Rgenta Therapeutics Launches with $20 Million Seed Investment PR Newswire

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC) - PR Newswire

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC) PR Newswire

Top Rgenta Therapeutics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant